BRAF V600 inhibitor (specialist)
Dabrafenib
Brand names: Tafinlar
Adult dose
Dose: 150mg BD (with trametinib for melanoma)
Route: Oral
Frequency: BD on empty stomach
Clinical pearls
- NICE TA396/TA547/TA764: BRAF V600-mutant melanoma, NSCLC, anaplastic thyroid (with trametinib)
- ESMO guidelines
- Specialist oncology — BRAF V600 mutation testing required
Contraindications
- Pregnancy
- G6PD deficiency (haemolysis risk)
- Hypersensitivity
Side effects
- Pyrexia (very common; with trametinib)
- Cutaneous SCC / new primary melanoma
- Uveitis
- Nephritis
- Cardiomyopathy
- QT prolongation
- Hyperglycaemia
Interactions
- Strong CYP3A4 inhibitors/inducers
- Acid-suppressants (reduced absorption)
- QT-prolonging drugs
Monitoring
- LVEF
- Skin
- BP
- Glucose
- Eye review
- Renal/LFTs
Reference: BNF; NICE TA396/TA547; ESMO; SmPC; https://bnf.nice.org.uk/drugs/dabrafenib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Breslow Thickness & Melanoma Staging · Melanoma
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis